Press Releases Year None20252024202320222021202020192018 Nov 07, 2025 Akero Therapeutics Presents New Analyses from Phase 2b SYMMETRY and HARMONY Trials of Efruxifermin at 76th Annual AASLD The Liver Meeting® 2025 Oct 09, 2025 Akero Therapeutics to be Acquired by Novo Nordisk for up to $5.2 Billion Oct 07, 2025 Akero Therapeutics to Present New Data from the Phase 2b SYMMETRY and HARMONY Studies of Efruxifermin at the 76th Annual AASLD The Liver Meeting® 2025 Aug 28, 2025 Akero Therapeutics to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference Aug 14, 2025 Akero Therapeutics Announces Lancet Publication of the Phase 2b HARMONY Clinical Trial Demonstrating 96 Weeks Treatment with EFX Reduced Liver Fibrosis in Patients with Pre-cirrhotic MASH Aug 08, 2025 Akero Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update Jun 03, 2025 Akero Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference May 28, 2025 Akero Therapeutics to Present at the Jefferies Global Healthcare Conference May 12, 2025 Akero Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update May 10, 2025 Akero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025 Current page 1 Page 2 Page 3 Next page next › Last page last » Displaying 1 - 10 of 22
Year None20252024202320222021202020192018 Nov 07, 2025 Akero Therapeutics Presents New Analyses from Phase 2b SYMMETRY and HARMONY Trials of Efruxifermin at 76th Annual AASLD The Liver Meeting® 2025 Oct 09, 2025 Akero Therapeutics to be Acquired by Novo Nordisk for up to $5.2 Billion Oct 07, 2025 Akero Therapeutics to Present New Data from the Phase 2b SYMMETRY and HARMONY Studies of Efruxifermin at the 76th Annual AASLD The Liver Meeting® 2025 Aug 28, 2025 Akero Therapeutics to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference Aug 14, 2025 Akero Therapeutics Announces Lancet Publication of the Phase 2b HARMONY Clinical Trial Demonstrating 96 Weeks Treatment with EFX Reduced Liver Fibrosis in Patients with Pre-cirrhotic MASH Aug 08, 2025 Akero Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update Jun 03, 2025 Akero Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference May 28, 2025 Akero Therapeutics to Present at the Jefferies Global Healthcare Conference May 12, 2025 Akero Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update May 10, 2025 Akero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025 Current page 1 Page 2 Page 3 Next page next › Last page last » Displaying 1 - 10 of 22
Nov 07, 2025 Akero Therapeutics Presents New Analyses from Phase 2b SYMMETRY and HARMONY Trials of Efruxifermin at 76th Annual AASLD The Liver Meeting® 2025
Oct 07, 2025 Akero Therapeutics to Present New Data from the Phase 2b SYMMETRY and HARMONY Studies of Efruxifermin at the 76th Annual AASLD The Liver Meeting® 2025
Aug 28, 2025 Akero Therapeutics to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
Aug 14, 2025 Akero Therapeutics Announces Lancet Publication of the Phase 2b HARMONY Clinical Trial Demonstrating 96 Weeks Treatment with EFX Reduced Liver Fibrosis in Patients with Pre-cirrhotic MASH
Aug 08, 2025 Akero Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
Jun 03, 2025 Akero Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
May 12, 2025 Akero Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
May 10, 2025 Akero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025
